Commentary: Adverse event profiles of PARP inhibitors: analysis of spontaneous reports submitted to FAERS.
作者信息
Schilder Jeanne M, Golembesky Amanda, Boyle Tirza Areli Calderón, Ye Gui Lan, Kuplast Judi
机构信息
GSK, Philadelphia, PA, United States.
GSK, Durham, NC, United States.
出版信息
Front Pharmacol. 2023 Aug 16;14:1241524. doi: 10.3389/fphar.2023.1241524. eCollection 2023.
Abstract
摘要
相似文献
1
Commentary: Adverse event profiles of PARP inhibitors: analysis of spontaneous reports submitted to FAERS.评论：PARP抑制剂的不良事件概况：对提交给FAERS的自发报告的分析
Front Pharmacol. 2023 Aug 16;14:1241524. doi: 10.3389/fphar.2023.1241524. eCollection 2023.
2
Adverse Event Profiles of PARP Inhibitors: Analysis of Spontaneous Reports Submitted to FAERS.PARP抑制剂的不良事件概况：对提交给FAERS的自发报告的分析
Front Pharmacol. 2022 Mar 25;13:851246. doi: 10.3389/fphar.2022.851246. eCollection 2022.
3
A real-world pharmacovigilance study of FDA adverse event reporting system (FAERS) events for niraparib.尼拉帕利的真实世界药物警戒研究：美国食品药品监督管理局不良事件报告系统（FAERS）事件。
Sci Rep. 2022 Nov 29;12(1):20601. doi: 10.1038/s41598-022-23726-4.
4
Myelodysplastic Syndrome/Acute Myeloid Leukemia Following the Use of Poly-ADP Ribose Polymerase (PARP) Inhibitors: A Real-World Analysis of Postmarketing Surveillance Data.使用聚腺苷二磷酸核糖聚合酶（PARP）抑制剂后发生的骨髓增生异常综合征/急性髓系白血病：上市后监测数据的真实世界分析
Front Pharmacol. 2022 Jun 15;13:912256. doi: 10.3389/fphar.2022.912256. eCollection 2022.
5
PARP inhibitor-related haemorrhages: What does the real-world study say?PARP抑制剂相关出血：真实世界研究有何发现？
Front Oncol. 2023 Feb 27;13:1070343. doi: 10.3389/fonc.2023.1070343. eCollection 2023.
6
Association between proton pump inhibitors and rhabdomyolysis risk: a post-marketing surveillance using FDA adverse event reporting system (FAERS) database.质子泵抑制剂与横纹肌溶解风险之间的关联：一项使用美国食品药品监督管理局不良事件报告系统（FAERS）数据库的上市后监测。
Ther Adv Drug Saf. 2023 Feb 27;14:20420986231154075. doi: 10.1177/20420986231154075. eCollection 2023.
7
Comprehensive Analysis of Adverse Events Induced by PARP Inhibitors Using JADER and Time to Onset.使用日本药品不良反应报告数据库（JADER）及不良反应发生时间对聚（ADP-核糖）聚合酶（PARP）抑制剂所致不良事件的综合分析
Life (Basel). 2022 Aug 31;12(9):1355. doi: 10.3390/life12091355.
8
Safety profiles of methylphenidate, amphetamine, and atomoxetine: analysis of spontaneous reports submitted to the food and drug administration adverse event reporting system.哌甲酯、苯丙胺和托莫西汀的安全性概况：对提交至美国食品药品监督管理局不良事件报告系统的自发报告的分析
Front Pharmacol. 2023 Aug 14;14:1208456. doi: 10.3389/fphar.2023.1208456. eCollection 2023.
9
ADEpedia-on-OHDSI: A next generation pharmacovigilance signal detection platform using the OHDSI common data model.ADEpedia-on-OHDSI：使用 OHDSI 通用数据模型的下一代药物警戒信号检测平台。
J Biomed Inform. 2019 Mar;91:103119. doi: 10.1016/j.jbi.2019.103119. Epub 2019 Feb 7.
10
SGLT2 inhibitors associated pancreatitis: signal identification through disproportionality analysis of spontaneous reports and review of case reports.SGLT2 抑制剂相关胰腺炎：通过自发报告的不匀称性分析和病例报告回顾识别信号。
Int J Clin Pharm. 2022 Dec;44(6):1425-1433. doi: 10.1007/s11096-022-01476-7. Epub 2022 Oct 12.
引用本文的文献
1
A real-world pharmacovigilance study of efgartigimod alfa in the FDA adverse event reporting system database.在FDA不良事件报告系统数据库中开展的关于阿伐吉莫德的真实世界药物警戒研究。
Front Pharmacol. 2025 Apr 16;16:1510992. doi: 10.3389/fphar.2025.1510992. eCollection 2025.
2
Disproportionality analysis of post-marketing safety concerns associated with selumetinib in the FDA adverse event reporting system.在FDA不良事件报告系统中对与司美替尼相关的上市后安全问题进行不成比例性分析。
Sci Rep. 2025 Mar 17;15(1):9218. doi: 10.1038/s41598-025-92741-y.
3
Assessing the risk of tumor lysis syndrome associated with the use of antineoplastic agents: a real-world pharmacovigilance study based on the FDA Adverse Event Reporting System database.评估使用抗肿瘤药物相关的肿瘤溶解综合征风险：一项基于美国食品药品监督管理局不良事件报告系统数据库的真实世界药物警戒研究。
Ther Adv Drug Saf. 2024 Sep 6;15:20420986241274909. doi: 10.1177/20420986241274909. eCollection 2024.
4
The real-world safety of oseltamivir and baloxavir marboxil in children: a disproportionality analysis of the FDA adverse event reporting system.奥司他韦和巴洛沙韦酯在儿童中的真实世界安全性：美国食品药品监督管理局不良事件报告系统的不成比例性分析
Front Pharmacol. 2024 Jul 10;15:1391003. doi: 10.3389/fphar.2024.1391003. eCollection 2024.
本文引用的文献
1
A real-world pharmacovigilance study of FDA adverse event reporting system (FAERS) events for niraparib.尼拉帕利的真实世界药物警戒研究：美国食品药品监督管理局不良事件报告系统（FAERS）事件。
Sci Rep. 2022 Nov 29;12(1):20601. doi: 10.1038/s41598-022-23726-4.
2
Adverse Event Profiles of PARP Inhibitors: Analysis of Spontaneous Reports Submitted to FAERS.PARP抑制剂的不良事件概况：对提交给FAERS的自发报告的分析
Front Pharmacol. 2022 Mar 25;13:851246. doi: 10.3389/fphar.2022.851246. eCollection 2022.
3
A Standardized Dataset of a Spontaneous Adverse Event Reporting System.一个自发不良事件报告系统的标准化数据集。
Healthcare (Basel). 2022 Feb 23;10(3):420. doi: 10.3390/healthcare10030420.
4
More extreme duplication in the U.S. FDA FAERS database and a suggested check point for disproportionality analysis.美国食品药品监督管理局不良事件报告系统（FAERS）数据库中更极端的重复情况以及不成比例分析的建议检查点。
Pharmacoepidemiol Drug Saf. 2021 Aug;30(8):1140-1141. doi: 10.1002/pds.5265. Epub 2021 May 13.
5
Data mining of the public version of the FDA Adverse Event Reporting System.对 FDA 不良事件报告系统公开版本的数据挖掘。
Int J Med Sci. 2013 Apr 25;10(7):796-803. doi: 10.7150/ijms.6048. Print 2013.
6
Use of variability in national and regional data to estimate the prevalence of lymphangioleiomyomatosis.利用国家和地区数据中的变异性来估计淋巴管平滑肌瘤病的流行率。
QJM. 2011 Nov;104(11):971-9. doi: 10.1093/qjmed/hcr116. Epub 2011 Jul 15.
7
Quantitative signal detection using spontaneous ADR reporting.使用自发药品不良反应报告进行定量信号检测。
Pharmacoepidemiol Drug Saf. 2009 Jun;18(6):427-36. doi: 10.1002/pds.1742.
8
'Extreme duplication' in the US FDA Adverse Events Reporting System database.美国食品药品监督管理局不良事件报告系统数据库中的“极度重复”现象。
Drug Saf. 2007;30(6):551-4. doi: 10.2165/00002018-200730060-00009.
9
Perspectives on the use of data mining in pharmaco-vigilance.药物警戒中数据挖掘应用的观点。
Drug Saf. 2005;28(11):981-1007. doi: 10.2165/00002018-200528110-00002.
Zotero 插件